Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reissue Patent
2007-08-28
2007-08-28
Low, Christopher S. F. (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C514S046000
Reissue Patent
active
10780553
ABSTRACT:
The present invention discloses a method for the prevention of atherosclerosis, its genesis, progression and restenosis in human patients undergoing treatments for arterial lesions such as PTA or atherectomy, and which may be accompanied by stent implantation. Further, the treatment method disclosed has applicability in all stages of atherosclerosis in which monocytes play a role. The compound utilized in the present method as the active agent is a 2-halo-2′-deoxyadenosine such as 2-chloro-deoxyadenosine (2-CdA). The treatment method of the present invention includes the administration of 14 doses of 2-CdA in the amount of 0.12 mg/kg. One dose is given intravenously before the coronary intervention, another is given intravenously after the intervention and the remaining twelve doses are given subcutaneously at weekly intervals over a subsequent three month period.
REFERENCES:
patent: 5106837 (1992-04-01), Carson et al.
patent: 5424296 (1995-06-01), Saven et al.
patent: 5510336 (1996-04-01), Saven et al.
Libby et al, Nouv Rev Fr Hematol, 34 Suppl. S47-53, 1992.
Faxon, David P., M.D., Chronic Inflamation, Clinical Trials and Remodeling; pp. 136-138; University of Southern California School of Medicine, Los Angeles, CA; Restenosis Summit VIII, 1996.
Gerrity, Ross G., PhD. The Role of the Monocyte in Atherogenesis, pp. 181 and 191; Research Division, The Cleveland Clinic Foundation, Cleveland, Ohio, Nov. 1, 1980.
Leibovich, S. J. PhD. et al., A Macrophage-Dependent Factor That Stimulates the Proliferation of Fibroblasts in Vitro; American Journal of Pathology; pp. 501, 508 and 511; Department of Pathology, University of Washington School of Medicine, Seattle, Washington, Apr. 23, 1976.
Ross, Russell, PhD., Mechanism of Disease Atherosclerosis—An Inflammatory Disease, The New England Journal of Medicine vol. 340, No. 2, pp. 115-126; Department of Pathology, University of Washington School of Medicine, Seattle, Washington; Jan. 14, 1999.
Ross, Russell, PhD. Medical Progress; The Pathogenesis of Athersclerosis—An Update; The New England Journal of Medicine vol. 314, No. 8, pp. 488, 493, 494; Department of Patholology, University of Washington School of Medicine, Seattle, Washington; Feb. 20, 1986.
Saven, Alan, M.D., et al.; Brief Communications, 2-Chlorodeoxyadenosine-induced Complete Remissions in Langerhans-Cell Histiocytosis, pp. 430-432; Reprinted from Annals of Internal Medicine, vol. 121, No. 6, Sep. 15, 1994.
Schwartz, Stephen M., et al; Remodeling: How Vessels Narrow, Clinical Trials and Remodeling; pp. 128-131; University of Washington, Seattle, WA; Massachusetts General Hospital, Boston, MA; and ZymoGenetics, Inc., Seattle WA, 1996.
Waltenberger, Johannes, M.D., Current Perspectives, Modulation of Growth Factor Action, Implications for the Treatment of Cardiovascular Diseases; Circulation, pp. 4083-4094; vol. 96, No. 11, Department of Internal Medicine II (Cardiology); Ulm University Medical Center, Ulm, Germany; Dec. 2, 1997.
Copy of Brochure for Leustatin.RTM. (cladribine) Injection; Ortho Biotech, Raritan, New Jersey, Dec. 1996.
Saven Alan
Schatz Richard A.
Conor Medsystems, Inc.
Gembeh Shirley V.
Low Christopher S. F.
Lynch Cindy A.
LandOfFree
Method for preventing restenosis using a substituted adenine... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for preventing restenosis using a substituted adenine..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for preventing restenosis using a substituted adenine... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3896517